{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:04:27Z","timestamp":1793660667231,"version":"4.5.1"},"reference-count":204,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-026-00686-x","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T08:02:06Z","timestamp":1772697726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Ovarian cancer"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3689-5956","authenticated-orcid":false,"given":"Clare L.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8840-7934","authenticated-orcid":false,"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6168-4942","authenticated-orcid":false,"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1280-5909","authenticated-orcid":false,"given":"Jung-Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0761-9562","authenticated-orcid":false,"given":"Asima","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-5262","authenticated-orcid":false,"given":"David S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8631-9762","authenticated-orcid":false,"given":"Elise C.","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"686_CR1","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","volume":"47","author":"G Gatta","year":"2011","unstructured":"Gatta, G. et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur. J. Cancer 47, 2493\u20132511 (2011).","journal-title":"Eur. J. Cancer"},{"key":"686_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","volume":"124","author":"J Prat","year":"2014","unstructured":"Prat, J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynaecol. Obstet. 124, 1\u20135 (2014). This staging classification enables prognostic and management decisions to be inferred.","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"686_CR3","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","volume":"24","author":"R Perets","year":"2013","unstructured":"Perets, R. et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24, 751\u2013765 (2013).","journal-title":"Cancer Cell"},{"key":"686_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev-pathol-020712-163949","volume":"9","author":"NN Nik","year":"2014","unstructured":"Nik, N. N., Vang, R., Shih Ie, M. & Kurman, R. J. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu. Rev. Pathol. 9, 27\u201345 (2014).","journal-title":"Annu. Rev. Pathol."},{"key":"686_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijgo.13878","volume":"155","author":"JS Berek","year":"2021","unstructured":"Berek, J. S., Renz, M., Kehoe, S., Kumar, L. & Friedlander, M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int. J. Gynaecol. Obstet. 155, 61\u201385 (2021).","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"686_CR6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1200\/JCO-24-02589","volume":"43","author":"S Gaillard","year":"2025","unstructured":"Gaillard, S. et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update. J. Clin. Oncol. 43, 868\u2013891 (2025). These guidelines describe the incorporation of neoadjuvant therapy, which has improved potential surgical debulking, known to impact patient survival.","journal-title":"J. Clin. Oncol."},{"key":"686_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.22.01010","volume":"41","author":"J Pfisterer","year":"2023","unstructured":"Pfisterer, J. et al. Optimal treatment duration of bevacizumab as front-line therapy for advanced ovarian cancer: AGO-OVAR 17 BOOST\/GINECO OV118\/ENGOT OV-15 open-label randomized phase III trial. J. Clin. Oncol. 41, 893\u2013902 (2023).","journal-title":"J. Clin. Oncol."},{"key":"686_CR8","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1200\/JCO.22.01934","volume":"40","author":"WP Tew","year":"2022","unstructured":"Tew, W. P., Lacchetti, C. & Kohn, E. C. Poly(ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J. Clin. Oncol. 40, 3878\u20133881 (2022). These guidelines describe how PARP inhibitor therapy should be used, with the potential of impacting treatment and outcomes for up to half of women with ovarian cancer, improving survival, and even resulting in cure in some.","journal-title":"J. Clin. Oncol."},{"key":"686_CR9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","volume":"33","author":"JS Frenel","year":"2022","unstructured":"Frenel, J. S. et al. Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial. Ann. Oncol. 33, 1021\u20131028 (2022).","journal-title":"Ann. Oncol."},{"key":"686_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","volume":"9","author":"M Markman","year":"1991","unstructured":"Markman, M. et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9, 389\u2013393 (1991).","journal-title":"J. Clin. Oncol."},{"key":"686_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cncy.22160","volume":"127","author":"B Kezlarian","year":"2019","unstructured":"Kezlarian, B. et al. Cytologic features of upper gynecologic tract adenocarcinomas exhibiting mesonephric-like differentiation. Cancer Cytopathol. 127, 521\u2013528 (2019).","journal-title":"Cancer Cytopathol."},{"key":"686_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153794","volume":"15","author":"F Wens","year":"2023","unstructured":"Wens, F. et al. Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT): patient characteristics, treatment, and outcome \u2014 a systematic review. Cancers 15, 3794 (2023).","journal-title":"Cancers"},{"key":"686_CR13","doi-asserted-by":"publisher","first-page":"7633","DOI":"10.1158\/1078-0432.CCR-17-1789","volume":"23","author":"SL Cooke","year":"2017","unstructured":"Cooke, S. L. et al. The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Clin. Cancer Res. 23, 7633\u20137640 (2017).","journal-title":"Clin. Cancer Res."},{"key":"686_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.pathol.2017.09.007","volume":"50","author":"RH Young","year":"2018","unstructured":"Young, R. H. Ovarian sex cord-stromal tumours and their mimics. Pathology 50, 5\u201315 (2018).","journal-title":"Pathology"},{"key":"686_CR15","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024). These global cancer statistics allow comparison of ovarian cancer impact and outcomes compared with other cancer types.","journal-title":"CA Cancer J. Clin."},{"key":"686_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13741-9","volume":"25","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Global, regional, and national burden of breast, cervical, uterine, and ovarian cancer and their risk factors among women from 1990 to 2021, and projections to 2050: findings from the Global Burden of Disease Study 2021. BMC Cancer 25, 330 (2025).","journal-title":"BMC Cancer"},{"key":"686_CR17","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"686_CR18","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.21037\/gs-20-325","volume":"9","author":"S Garzon","year":"2020","unstructured":"Garzon, S. et al. Secondary and tertiary ovarian cancer recurrence: what is the best management?\u00a0Gland. Surg. 9, 1118\u20131129 (2020).","journal-title":"Gland. Surg."},{"key":"686_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2025.100582","volume":"44","author":"A Bajwa","year":"2025","unstructured":"Bajwa, A. et al. Challenges and opportunities in ovarian cancer care: a qualitative study of clinician perspectives from 24 low- and middle-income countries. J. Cancer Policy 44, 100582 (2025).","journal-title":"J. Cancer Policy"},{"key":"686_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ygyno.2012.12.016","volume":"129","author":"G Chornokur","year":"2013","unstructured":"Chornokur, G., Amankwah, E. K., Schildkraut, J. M. & Phelan, C. M. Global ovarian cancer health disparities. Gynecol. Oncol. 129, 258\u2013264 (2013).","journal-title":"Gynecol. Oncol."},{"key":"686_CR21","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/j.lanogw.2025.100047","volume":"1","author":"G Funston","year":"2025","unstructured":"Funston, G. et al. Experiences of women with ovarian cancer in 22 low-income and middle-income countries (Every Woman Study LMICs): a cross-sectional study. Lancet Obstet. Gynaecol. Womens Health 1, e302\u2013e313 (2025).","journal-title":"Lancet Obstet. Gynaecol. Womens Health"},{"key":"686_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-025-06277-9","volume":"151","author":"Y Ren","year":"2025","unstructured":"Ren, Y., Xu, R., Wang, Y., Su, L. & Su, J. Global, regional, and national burden of ovarian cancer in women aged 45+ from 1990 to 2021 and projections for 2050: a systematic analysis based on the 2021 Global Burden of Disease Study. J. Cancer Res. Clin. Oncol. 151, 225 (2025).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"686_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/GO-24-00313","volume":"11","author":"B Hutchinson","year":"2025","unstructured":"Hutchinson, B. et al. Socioeconomic burden of ovarian cancer in 11 countries. JCO Glob. Oncol. 11, e2400313 (2025).","journal-title":"JCO Glob. Oncol."},{"key":"686_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000404","volume":"3","author":"SM Silverwood","year":"2024","unstructured":"Silverwood, S. M. et al. Assessing the rates of false-positive ovarian cancer screenings and surgical interventions associated with screening tools: a systematic review. BMJ Oncol. 3, e000404 (2024).","journal-title":"BMJ Oncol."},{"key":"686_CR25","unstructured":"American Cancer Society. Cancer Facts & Figures 2020 (American Cancer Society, 2020)."},{"key":"686_CR26","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1002\/ijc.30676","volume":"140","author":"SB Coburn","year":"2017","unstructured":"Coburn, S. B., Bray, F., Sherman, M. E. & Trabert, B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int. J. Cancer 140, 2451\u20132460 (2017).","journal-title":"Int. J. Cancer"},{"key":"686_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102983","volume":"79","author":"YF Wei","year":"2025","unstructured":"Wei, Y. F. et al. Worldwide patterns and trends in ovarian cancer incidence by histological subtype: a population-based analysis from 1988 to 2017. EClinicalMedicine 79, 102983 (2025).","journal-title":"EClinicalMedicine"},{"key":"686_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/GCO.0000000000000340","volume":"29","author":"PT Kroeger Jr.","year":"2017","unstructured":"Kroeger, P. T. Jr. & Drapkin, R. Pathogenesis and heterogeneity of ovarian cancer. Curr. Opin. Obstet. Gynecol. 29, 26\u201334 (2017).","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"686_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djy071","volume":"111","author":"LC Peres","year":"2019","unstructured":"Peres, L. C. et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J. Natl Cancer Inst. 111, 60\u201368 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"686_CR30","doi-asserted-by":"publisher","first-page":"i53","DOI":"10.1093\/annonc\/mdw087","volume":"27","author":"TJ Perren","year":"2016","unstructured":"Perren, T. J. Mucinous epithelial ovarian carcinoma. Ann. Oncol. 27, i53\u2013i57 (2016).","journal-title":"Ann. Oncol."},{"key":"686_CR31","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonzalez-Martin","year":"2023","unstructured":"Gonzalez-Martin, A. et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 833\u2013848 (2023).","journal-title":"Ann. Oncol."},{"key":"686_CR32","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","volume":"4","author":"PA Konstantinopoulos","year":"2023","unstructured":"Konstantinopoulos, P. A. & Matulonis, U. A. Clinical and translational advances in ovarian cancer therapy. Nat. Cancer 4, 1239\u20131257 (2023).","journal-title":"Nat. Cancer"},{"key":"686_CR33","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41571-023-00819-1","volume":"20","author":"AC Veneziani","year":"2023","unstructured":"Veneziani, A. C. et al. Heterogeneity and treatment landscape of ovarian carcinoma. Nat. Rev. Clin. Oncol. 20, 820\u2013842 (2023). This review provides a broad description of the treatment landscape of different types of ovarian cancer.","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"686_CR34","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/ijgc-2020-001656","volume":"31","author":"Y Iida","year":"2021","unstructured":"Iida, Y., Okamoto, A., Hollis, R. L., Gourley, C. & Herrington, C. S. Clear cell carcinoma of the ovary: a clinical and molecular perspective. Int. J. Gynecol. Cancer 31, 605\u2013616 (2021).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"686_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08061-7","volume":"21","author":"C Zhu","year":"2021","unstructured":"Zhu, C. et al. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study. BMC Cancer 21, 322 (2021).","journal-title":"BMC Cancer"},{"key":"686_CR36","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ygyno.2022.10.020","volume":"169","author":"SA Ackroyd","year":"2023","unstructured":"Ackroyd, S. A. et al. Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma. Gynecol. Oncol. 169, 164\u2013171 (2023).","journal-title":"Gynecol. Oncol."},{"key":"686_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112708","volume":"14","author":"E Whelan","year":"2022","unstructured":"Whelan, E. et al. Risk factors for ovarian cancer: an umbrella review of the literature. Cancers 14, 2708 (2022).","journal-title":"Cancers"},{"key":"686_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005424","author":"I Madakkatel","year":"2025","unstructured":"Madakkatel, I. et al. Large-scale analysis to identify risk factors for ovarian cancer. Int. J. Gynecol. Cancer https:\/\/doi.org\/10.1136\/ijgc-2024-005424 (2025).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"686_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ygyno.2018.05.011","volume":"150","author":"J Kotsopoulos","year":"2018","unstructured":"Kotsopoulos, J. et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol. Oncol. 150, 85\u201391 (2018).","journal-title":"Gynecol. Oncol."},{"key":"686_CR40","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.trecan.2016.10.014","volume":"2","author":"SP Ivy","year":"2016","unstructured":"Ivy, S. P., de Bono, J. & Kohn, E. C. The \u2018pushmi-pullyu\u2019 of DNA repair: clinical synthetic lethality. Trends Cancer 2, 646\u2013656 (2016). This description of the context in which DNA repair inhibition is likely to be successful in ovarian cancer underpins the current clinical trials and research required to solve the next major challenge \u2014 PARP inhibitor resistance.","journal-title":"Trends Cancer"},{"key":"686_CR41","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","volume":"20","author":"KP Pennington","year":"2014","unstructured":"Pennington, K. P. et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 20, 764\u2013775 (2014). This description of DNA repair gene mutations and impact on treatment outcomes predicted the following decade of clinical trial outcomes.","journal-title":"Clin. Cancer Res."},{"key":"686_CR42","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.19.02960","volume":"38","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos, P. A. et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J. Clin. Oncol. 38, 1222\u20131245 (2020). These guidelines provide an approach to best practice of germline and somatic tumour testing of ovarian cancer.","journal-title":"J. Clin. Oncol."},{"key":"686_CR43","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402\u20132416 (2017).","journal-title":"JAMA"},{"key":"686_CR44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejca.2015.12.005","volume":"55","author":"JM Helder-Woolderink","year":"2016","unstructured":"Helder-Woolderink, J. M. et al. Ovarian cancer in Lynch syndrome; a systematic review. Eur. J. Cancer 55, 65\u201373 (2016).","journal-title":"Eur. J. Cancer"},{"key":"686_CR45","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/cam4.3688","volume":"10","author":"R Hodan","year":"2021","unstructured":"Hodan, R. et al. Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer. Cancer Med. 10, 1012\u20131017 (2021).","journal-title":"Cancer Med."},{"key":"686_CR46","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1200\/JCO.2019.37.15_suppl.1521","volume":"37","author":"M Scaranti","year":"2019","unstructured":"Scaranti, M. et al. Prevalence and clinical implications of mismatch repair (MMR) deficiency in unselected non-serous epithelial ovarian cancer (EOC) patients (pts) [abstract]. J. Clin. Oncol. 37, 1521 (2019).","journal-title":"J. Clin. Oncol."},{"key":"686_CR47","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1200\/JCO.2016.66.8178","volume":"34","author":"N Wentzensen","year":"2016","unstructured":"Wentzensen, N. et al. Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium. J. Clin. Oncol. 34, 2888\u20132898 (2016).","journal-title":"J. Clin. Oncol."},{"key":"686_CR48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmed","year":"2010","unstructured":"Ahmed, A. A. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221, 49\u201356 (2010). The importance of p53, the guardian of the genome, in very early development of nearly all ovarian cancers paves the way for future potential therapeutic approaches.","journal-title":"J. Pathol."},{"key":"686_CR49","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1073\/pnas.1117135109","volume":"109","author":"J Kim","year":"2012","unstructured":"Kim, J. et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc. Natl Acad. Sci. USA 109, 3921\u20133926 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"686_CR50","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15, 668\u2013679 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"686_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100144","volume":"6","author":"NYL Ngoi","year":"2021","unstructured":"Ngoi, N. Y. L. & Tan, D. S. P. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? ESMO Open. 6, 100144 (2021).","journal-title":"ESMO Open."},{"key":"686_CR52","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.ygyno.2020.12.007","volume":"160","author":"TS Ghezelayagh","year":"2021","unstructured":"Ghezelayagh, T. S. et al. Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations. Gynecol. Oncol. 160, 786\u2013792 (2021).","journal-title":"Gynecol. Oncol."},{"key":"686_CR53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","volume":"60","author":"JA Ledermann","year":"2016","unstructured":"Ledermann, J. A., Drew, Y. & Kristeleit, R. S. Homologous recombination deficiency and ovarian cancer. Eur. J. Cancer 60, 49\u201358 (2016).","journal-title":"Eur. J. Cancer"},{"key":"686_CR54","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231157644","volume":"15","author":"AC Veneziani","year":"2023","unstructured":"Veneziani, A. C., Scott, C., Wakefield, M. J., Tinker, A. V. & Lheureux, S. Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer. Ther. Adv. Med. Oncol. 15, 17588359231157644 (2023).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"686_CR55","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1002\/cncr.24987","volume":"116","author":"N Nakayama","year":"2010","unstructured":"Nakayama, N. et al. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 116, 2621\u20132634 (2010).","journal-title":"Cancer"},{"key":"686_CR56","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1136\/ijgc-2020-001277","volume":"30","author":"NY Ngoi","year":"2020","unstructured":"Ngoi, N. Y., Sundararajan, V. & Tan, D. S. Exploiting replicative stress in gynecological cancers as a therapeutic strategy. Int. J. Gynecol. Cancer 30, 1224\u20131238 (2020).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"686_CR57","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"AM Patch","year":"2015","unstructured":"Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489\u2013494 (2015).","journal-title":"Nature"},{"key":"686_CR58","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","volume":"363","author":"KC Wiegand","year":"2010","unstructured":"Wiegand, K. C. et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363, 1532\u20131543 (2010).","journal-title":"N. Engl. J. Med."},{"key":"686_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00649-8","volume":"14","author":"M Sun","year":"2023","unstructured":"Sun, M. & Jiang, W. Ovarian clear cell carcinoma with or without endometriosis origin in a single institution cohort. Discov. Oncol. 14, 39 (2023).","journal-title":"Discov. Oncol."},{"key":"686_CR60","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.ygyno.2021.06.033","volume":"162","author":"A Gadducci","year":"2021","unstructured":"Gadducci, A. et al. Clear cell carcinoma of the ovary: epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecol. Oncol. 162, 741\u2013750 (2021).","journal-title":"Gynecol. Oncol."},{"key":"686_CR61","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ygyno.2022.01.012","volume":"164","author":"G Bogani","year":"2022","unstructured":"Bogani, G. et al. Clear cell carcinoma of the endometrium. Gynecol. Oncol. 164, 658\u2013666 (2022).","journal-title":"Gynecol. Oncol."},{"key":"686_CR62","doi-asserted-by":"publisher","first-page":"6773","DOI":"10.7150\/jca.61107","volume":"12","author":"Y Sun","year":"2021","unstructured":"Sun, Y. & Liu, G. Endometriosis-associated ovarian clear cell carcinoma: a special entity? J. Cancer 12, 6773\u20136786 (2021).","journal-title":"J. Cancer"},{"key":"686_CR63","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/0008-5472.CAN-23-1362","volume":"84","author":"I Beddows","year":"2024","unstructured":"Beddows, I. et al. Cell state of origin impacts development of distinct endometriosis-related ovarian carcinoma histotypes. Cancer Res. 84, 26\u201338 (2024).","journal-title":"Cancer Res."},{"key":"686_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1162786","volume":"14","author":"KE Collins","year":"2023","unstructured":"Collins, K. E. et al. Transcriptomic analyses of ovarian clear-cell carcinoma with concurrent endometriosis. Front. Endocrinol. 14, 1162786 (2023).","journal-title":"Front. Endocrinol."},{"key":"686_CR65","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1158\/1078-0432.CCR-21-3817","volume":"28","author":"KL Bolton","year":"2022","unstructured":"Bolton, K. L. et al. Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes. Clin. Cancer Res. 28, 4947\u20134956 (2022).","journal-title":"Clin. Cancer Res."},{"key":"686_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.668151","volume":"11","author":"S Chen","year":"2021","unstructured":"Chen, S. et al. A review of the clinical characteristics and novel molecular subtypes of endometrioid ovarian cancer. Front. Oncol. 11, 668151 (2021).","journal-title":"Front. Oncol."},{"key":"686_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18819-5","volume":"11","author":"RL Hollis","year":"2020","unstructured":"Hollis, R. L. et al. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome. Nat. Commun. 11, 4995 (2020).","journal-title":"Nat. Commun."},{"key":"686_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102497","volume":"112","author":"TA Zwimpfer","year":"2023","unstructured":"Zwimpfer, T. A. et al. Low grade serous ovarian cancer \u2014 a rare disease with increasing therapeutic options. Cancer Treat. Rev. 112, 102497 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"686_CR69","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/ijgc-2022-003677","volume":"33","author":"L Cobb","year":"2023","unstructured":"Cobb, L. & Gershenson, D. Novel therapeutics in low-grade serous ovarian cancer. Int. J. Gynecol. Cancer 33, 377\u2013384 (2023).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"686_CR70","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/cncr.27782","volume":"119","author":"RN Grisham","year":"2013","unstructured":"Grisham, R. N. et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 119, 548\u2013554 (2013).","journal-title":"Cancer"},{"key":"686_CR71","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-21-4183","volume":"28","author":"B Manning-Geist","year":"2022","unstructured":"Manning-Geist, B. et al. MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. Clin. Cancer Res. 28, 4456\u20134465 (2022).","journal-title":"Clin. Cancer Res."},{"key":"686_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10010052","volume":"10","author":"A Babaier","year":"2020","unstructured":"Babaier, A. & Ghatage, P. Mucinous cancer of the ovary: overview and current status. Diagnostics 10, 52 (2020).","journal-title":"Diagnostics"},{"key":"686_CR73","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJMra1813254","volume":"380","author":"P Morice","year":"2019","unstructured":"Morice, P., Gouy, S. & Leary, A. Mucinous ovarian carcinoma. N. Engl. J. Med. 380, 1256\u20131266 (2019).","journal-title":"N. Engl. J. Med."},{"key":"686_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11862-x","volume":"10","author":"D Cheasley","year":"2019","unstructured":"Cheasley, D. et al. The molecular origin and taxonomy of mucinous ovarian carcinoma. Nat. Commun. 10, 3935 (2019).","journal-title":"Nat. Commun."},{"key":"686_CR75","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ygyno.2019.12.015","volume":"156","author":"KL Gorringe","year":"2020","unstructured":"Gorringe, K. L. et al. Therapeutic options for mucinous ovarian carcinoma. Gynecol. Oncol. 156, 552\u2013560 (2020).","journal-title":"Gynecol. Oncol."},{"key":"686_CR76","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/ijgc-2022-003658","volume":"33","author":"D Nugawela","year":"2023","unstructured":"Nugawela, D. & Gorringe, K. L. Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials. Int. J. Gynecol. Cancer 33, 102\u2013108 (2023).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"686_CR77","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1158\/0008-5472.CAN-21-4012","volume":"82","author":"GY Ho","year":"2022","unstructured":"Ho, G. Y. et al. Epithelial-to-mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule targeting with eribulin. Cancer Res. 82, 4457\u20134473 (2022).","journal-title":"Cancer Res."},{"key":"686_CR78","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.semcancer.2019.10.006","volume":"61","author":"HE Barker","year":"2020","unstructured":"Barker, H. E. & Scott, C. L. Genomics of gynaecological carcinosarcomas and future treatment options. Semin. Cancer Biol. 61, 110\u2013120 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"686_CR79","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/COC.0000000000001056","volume":"46","author":"K Ramphal","year":"2023","unstructured":"Ramphal, K., Hadfield, M. J., Bandera, C. M., Hart, J. & Dizon, D. S. Genomic and molecular characteristics of ovarian carcinosarcoma. Am. J. Clin. Oncol. 46, 572\u2013576 (2023).","journal-title":"Am. J. Clin. Oncol."},{"key":"686_CR80","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/jnci\/djae151","volume":"116","author":"SA Narod","year":"2024","unstructured":"Narod, S. A. et al. Incidence of peritoneal cancer after oophorectomy among BRCA1 and BRCA2 mutation carriers. J. Natl Cancer Inst. 116, 1753\u20131760 (2024).","journal-title":"J. Natl Cancer Inst."},{"key":"686_CR81","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1200\/JCO.21.02016","volume":"40","author":"MP Steenbeek","year":"2022","unstructured":"Steenbeek, M. P. et al. Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy: a systematic review and individual patient data meta-analysis. J. Clin. Oncol. 40, 1879\u20131891 (2022).","journal-title":"J. Clin. Oncol."},{"key":"686_CR82","volume":"6","author":"Z Li","year":"2023","unstructured":"Li, Z., Fang, X. & Wang, S. Omentum provides a special cell microenvironment for ovarian cancer. Cancer Rep. 6, e1858 (2023).","journal-title":"Cancer Rep."},{"key":"686_CR83","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ygyno.2010.11.035","volume":"121","author":"RA Burger","year":"2011","unstructured":"Burger, R. A. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol. Oncol. 121, 230\u2013238 (2011).","journal-title":"Gynecol. Oncol."},{"key":"686_CR84","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"686_CR85","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203\u2013213 (2003). This description of the impact of immune cells on ovarian cancer treatment outcomes suggests that addressing this major challenge is crucial.","journal-title":"N. Engl. J. Med."},{"key":"686_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1328651","volume":"14","author":"F Blanc-Durand","year":"2023","unstructured":"Blanc-Durand, F., Clemence Wei Xian, L. & Tan, D. S. P. Targeting the immune microenvironment for ovarian cancer therapy. Front. Immunol. 14, 1328651 (2023).","journal-title":"Front. Immunol."},{"key":"686_CR87","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/cncr.22371","volume":"109","author":"BA Goff","year":"2007","unstructured":"Goff, B. A. et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 109, 221\u2013227 (2007).","journal-title":"Cancer"},{"key":"686_CR88","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.amepre.2015.09.023","volume":"50","author":"MH Ebell","year":"2016","unstructured":"Ebell, M. H., Culp, M. B. & Radke, T. J. A systematic review of symptoms for the diagnosis of ovarian cancer. Am. J. Prev. Med. 50, 384\u2013394 (2016).","journal-title":"Am. J. Prev. Med."},{"key":"686_CR89","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S1470-2045(07)70357-1","volume":"8","author":"A Sevinc","year":"2007","unstructured":"Sevinc, A., Adli, M., Kalender, M. E. & Camci, C. Benign causes of increased serum CA-125 concentration. Lancet Oncol. 8, 1054\u20131055 (2007).","journal-title":"Lancet Oncol."},{"key":"686_CR90","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1200\/GO.21.00085","volume":"7","author":"VD Vanderpuye","year":"2021","unstructured":"Vanderpuye, V. D. et al. Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline. JCO Glob. Oncol. 7, 1032\u20131066 (2021). These guidelines describe the diagnostic approach to women with an ovarian mass and appropriate approaches to treatment.","journal-title":"JCO Glob. Oncol."},{"key":"686_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123795","volume":"2","author":"D Franciszek Dluski","year":"2020","unstructured":"Franciszek Dluski, D., Mierzynski, R., Poniedzialek-Czajkowska, E. & Leszczynska-Gorzelak, B. Ovarian cancer and pregnancy \u2014 a current problem in perinatal medicine: a comprehensive review. Cancers 2, 3795 (2020).","journal-title":"Cancers"},{"key":"686_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2024.100053","volume":"35","author":"R Fruscio","year":"2025","unstructured":"Fruscio, R. et al. Epithelial ovarian cancer and borderline tumors during pregnancy: a report from the International Network on Cancer, Infertility, and Pregnancy. Int. J. Gynecol. Cancer 35, 100053 (2025).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"686_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1104694","volume":"14","author":"T Miyamoto","year":"2023","unstructured":"Miyamoto, T., Murphy, B. & Zhang, N. Intraperitoneal metastasis of ovarian cancer: new insights on resident macrophages in the peritoneal cavity. Front. Immunol. 14, 1104694 (2023).","journal-title":"Front. Immunol."},{"key":"686_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1405361","volume":"14","author":"F Guffanti","year":"2024","unstructured":"Guffanti, F., Mengoli, I. & Damia, G. Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches. Front. Oncol. 14, 1405361 (2024).","journal-title":"Front. Oncol."},{"key":"686_CR95","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","volume":"35","author":"JA Ledermann","year":"2024","unstructured":"Ledermann, J. A. et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann. Oncol. 35, 248\u2013266 (2024). This consensus conference report details the pathology and molecular biology of ovarian cancer.","journal-title":"Ann. Oncol."},{"key":"686_CR96","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO-25-00112","volume":"43","author":"SN Banerjee","year":"2025","unstructured":"Banerjee, S. N. et al. Efficacy and safety of avutometinib \u00b1 defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60\/GOG-3052\/RAMP 201. J. Clin. Oncol. 43, 2782\u20132792 (2025).","journal-title":"J. Clin. Oncol."},{"key":"686_CR97","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis, U. A. et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J. Clin. Oncol. 41, 2436\u20132445 (2023).","journal-title":"J. Clin. Oncol."},{"key":"686_CR98","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1158\/1078-0432.CCR-23-0991","volume":"29","author":"A Dilawari","year":"2023","unstructured":"Dilawari, A. et al. FDA approval summary: mirvetuximab soravtansine-gynx for FR\u03b1-positive, platinum-resistant ovarian cancer. Clin. Cancer Res. 29, 3835\u20133840 (2023).","journal-title":"Clin. Cancer Res."},{"key":"686_CR99","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","volume":"397","author":"U Menon","year":"2021","unstructured":"Menon, U. et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 397, 2182\u20132193 (2021). This large trial shows that screening for ovarian cancer is not yet effective as it is does not improve survival.","journal-title":"Lancet"},{"key":"686_CR100","doi-asserted-by":"publisher","first-page":"251S","DOI":"10.1016\/S0197-2456(00)00097-0","volume":"21","author":"JK Gohagan","year":"2000","unstructured":"Gohagan, J. K. et al. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control. Clin. Trials 21, 251S\u2013272S (2000).","journal-title":"Control. Clin. Trials"},{"key":"686_CR101","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2011.766","volume":"305","author":"SS Buys","year":"2011","unstructured":"Buys, S. S. et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305, 2295\u20132303 (2011).","journal-title":"JAMA"},{"key":"686_CR102","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1525-1438.2007.01035.x","volume":"18","author":"H Kobayashi","year":"2008","unstructured":"Kobayashi, H. et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int. J. Gynecol. Cancer 18, 414\u2013420 (2008).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"686_CR103","doi-asserted-by":"publisher","first-page":"264","DOI":"10.5694\/mja2.52227","volume":"220","author":"M Sideris","year":"2024","unstructured":"Sideris, M., Menon, U. & Manchanda, R. Screening and prevention of ovarian cancer. Med. J. Aust. 220, 264\u2013274 (2024).","journal-title":"Med. J. Aust."},{"key":"686_CR104","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","volume":"32","author":"AP Finch","year":"2014","unstructured":"Finch, A. P. et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J. Clin. Oncol. 32, 1547\u20131553 (2014).","journal-title":"J. Clin. Oncol."},{"key":"686_CR105","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/AOG.0b013e3182864350","volume":"121","author":"WH Parker","year":"2013","unstructured":"Parker, W. H. et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses\u2019 Health Study. Obstet. Gynecol. 121, 709\u2013716 (2013).","journal-title":"Obstet. Gynecol."},{"key":"686_CR106","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2017.28.e3","volume":"28","author":"YJ Lee","year":"2017","unstructured":"Lee, Y. J. et al. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers. J. Gynecol. Oncol. 28, e3 (2017).","journal-title":"J. Gynecol. Oncol."},{"key":"686_CR107","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky061","volume":"2","author":"G Samimi","year":"2018","unstructured":"Samimi, G., Trabert, B., Geczik, A. M., Duggan, M. A. & Sherman, M. E. Population frequency of serous tubal intraepithelial carcinoma (STIC) in clinical practice using SEE-Fim protocol. JNCI Cancer Spectr. 2, pky061 (2018).","journal-title":"JNCI Cancer Spectr."},{"key":"686_CR108","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","volume":"30","author":"F Medeiros","year":"2006","unstructured":"Medeiros, F. et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 30, 230\u2013236 (2006).","journal-title":"Am. J. Surg. Pathol."},{"key":"686_CR109","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT04294927 (2025)."},{"key":"686_CR110","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT04251052 (2026)."},{"key":"686_CR111","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.47343","volume":"5","author":"GE Hanley","year":"2022","unstructured":"Hanley, G. E. et al. Outcomes from opportunistic salpingectomy for ovarian cancer prevention. JAMA Netw. Open. 5, e2147343 (2022).","journal-title":"JAMA Netw. Open."},{"key":"686_CR112","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly, M. B. et al. Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 19, 77\u2013102 (2021).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"686_CR113","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines: Breast, Ovarian, and Pancreatic Cancer Genetic Assessment. Version 1.2025 (National Comprehensive Cancer Network, 2025)."},{"key":"686_CR114","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","volume":"30","author":"N Colombo","year":"2019","unstructured":"Colombo, N. et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann. Oncol. 30, 672\u2013705 (2019).","journal-title":"Ann. Oncol."},{"key":"686_CR115","unstructured":"European Society of Gynaecological Oncology. Ovarian Cancer Pocket Guidelines: based on ESGO\u2013ESMO\u2013ESP consensus conference recommendations on ovarian cancer (European Society of Gynaecological Oncology, 2025)."},{"key":"686_CR116","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","volume":"34","author":"C Sessa","year":"2023","unstructured":"Sessa, C. et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann. Oncol. 34, 33\u201347 (2023).","journal-title":"Ann. Oncol."},{"key":"686_CR117","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","volume":"19","author":"I Vergote","year":"2018","unstructured":"Vergote, I. et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 19, 1680\u20131687 (2018).","journal-title":"Lancet Oncol."},{"key":"686_CR118","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1808424","volume":"380","author":"P Harter","year":"2019","unstructured":"Harter, P. et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N. Engl. J. Med. 380, 822\u2013832 (2019).","journal-title":"N. Engl. J. Med."},{"key":"686_CR119","doi-asserted-by":"publisher","first-page":"e602","DOI":"10.1016\/S1470-2045(24)00262-6","volume":"25","author":"P Morice","year":"2024","unstructured":"Morice, P. et al. Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE. Lancet Oncol. 25, e602\u2013e610 (2024).","journal-title":"Lancet Oncol."},{"key":"686_CR120","first-page":"723","volume":"18","author":"A Straubhar","year":"2020","unstructured":"Straubhar, A., Chi, D. S. & Long Roche, K. Update on the role of surgery in the management of advanced epithelial ovarian cancer. Clin. Adv. Hematol. Oncol. 18, 723\u2013731 (2020).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"686_CR121","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L. & Montz, F. J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20, 1248\u20131259 (2002).","journal-title":"J. Clin. Oncol."},{"key":"686_CR122","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","volume":"130","author":"SJ Chang","year":"2013","unstructured":"Chang, S. J., Hodeib, M., Chang, J. & Bristow, R. E. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol. Oncol. 130, 493\u2013498 (2013).","journal-title":"Gynecol. Oncol."},{"key":"686_CR123","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.annonc.2021.07.004","volume":"32","author":"N Colombo","year":"2021","unstructured":"Colombo, N. & Ledermann, J. A. Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines. Ann. Oncol. 32, 1300\u20131303 (2021). These guidelines provide treatment recommendations for newly diagnosed ovarian cancer.","journal-title":"Ann. Oncol."},{"key":"686_CR124","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/ijgc-2020-001248","volume":"30","author":"C Fotopoulou","year":"2020","unstructured":"Fotopoulou, C. et al. Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. Int. J. Gynecol. Cancer 30, 436\u2013440 (2020).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"686_CR125","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","volume":"24","author":"SL Aronson","year":"2023","unstructured":"Aronson, S. L. et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol. 24, 1109\u20131118 (2023).","journal-title":"Lancet Oncol."},{"key":"686_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133114","volume":"13","author":"W Ceelen","year":"2021","unstructured":"Ceelen, W., Demuytere, J. & de Hingh, I. Hyperthermic intraperitoneal chemotherapy: a critical review. Cancers 13, 3114 (2021).","journal-title":"Cancers"},{"key":"686_CR127","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","volume":"19","author":"DK Armstrong","year":"2021","unstructured":"Armstrong, D. K. et al. Ovarian cancer, version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc Netw. 19, 191\u2013226 (2021).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"686_CR128","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1200\/JCO.19.01009","volume":"37","author":"KS Tewari","year":"2019","unstructured":"Tewari, K. S. et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J. Clin. Oncol. 37, 2317\u20132328 (2019).","journal-title":"J. Clin. Oncol."},{"key":"686_CR129","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza, A. M. et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 16, 928\u2013936 (2015).","journal-title":"Lancet Oncol."},{"key":"686_CR130","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote, I. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363, 943\u2013953 (2010).","journal-title":"N. Engl. J. Med."},{"key":"686_CR131","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1200\/EDBK_158927","volume":"35","author":"C Gourley","year":"2016","unstructured":"Gourley, C., Walker, J. L. & Mackay, H. J. Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer. Am. Soc. Clin. Oncol. Educ. Book. 35, 143\u2013151 (2016).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"686_CR132","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1200\/JCO.18.01568","volume":"37","author":"JL Walker","year":"2019","unstructured":"Walker, J. L. et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology\/Gynecologic Oncology Group study. J. Clin. Oncol. 37, 1380\u20131390 (2019).","journal-title":"J. Clin. Oncol."},{"key":"686_CR133","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1200\/JCO.2015.61.4776","volume":"33","author":"AA Wright","year":"2015","unstructured":"Wright, A. A. et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J. Clin. Oncol. 33, 2841\u20132847 (2015).","journal-title":"J. Clin. Oncol."},{"key":"686_CR134","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200225","volume":"2","author":"S Nagao","year":"2023","unstructured":"Nagao, S. et al. Intraperitoneal carboplatin for ovarian cancer \u2014 a phase 2\/3 trial. NEJM Evid. 2, EVIDoa2200225 (2023).","journal-title":"NEJM Evid."},{"key":"686_CR135","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","volume":"394","author":"AR Clamp","year":"2019","unstructured":"Clamp, A. R. et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet 394, 2084\u20132095 (2019).","journal-title":"Lancet"},{"key":"686_CR136","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee, S. et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 1721\u20131731 (2021).","journal-title":"Lancet Oncol."},{"key":"686_CR137","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro, P. et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J. Clin. Oncol. 41, 609\u2013617 (2023).","journal-title":"J. Clin. Oncol."},{"key":"686_CR138","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard, I. et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann. Oncol. 34, 681\u2013692 (2023).","journal-title":"Ann. Oncol."},{"key":"686_CR139","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416\u20132428 (2019).","journal-title":"N. Engl. J. Med."},{"key":"686_CR140","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391\u20132402 (2019).","journal-title":"N. Engl. J. Med."},{"key":"686_CR141","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk, B. J. et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann. Oncol. 35, 981\u2013992 (2024).","journal-title":"Ann. Oncol."},{"key":"686_CR142","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1200\/JCO.22.01003","volume":"40","author":"BJ Monk","year":"2022","unstructured":"Monk, B. J. et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45). J. Clin. Oncol. 40, 3952\u20133964 (2022).","journal-title":"J. Clin. Oncol."},{"key":"686_CR143","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","volume":"7","author":"O Kondrashova","year":"2017","unstructured":"Kondrashova, O. et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 7, 984\u2013998 (2017).","journal-title":"Cancer Discov."},{"key":"686_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22582-6","volume":"12","author":"EM Swisher","year":"2021","unstructured":"Swisher, E. M. et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (parts 1 and 2). Nat. Commun. 12, 2487 (2021).","journal-title":"Nat. Commun."},{"key":"686_CR145","doi-asserted-by":"publisher","first-page":"S1223","DOI":"10.1016\/j.annonc.2024.08.2269","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk, B. J. et al. ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC) [abstract LBA30]. Ann. Oncol. 35, S1223\u2013S1224 (2024).","journal-title":"Ann. Oncol."},{"key":"686_CR146","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","volume":"29","author":"S Pignata","year":"2011","unstructured":"Pignata, S. et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J. Clin. Oncol. 29, 3628\u20133635 (2011).","journal-title":"J. Clin. Oncol."},{"key":"686_CR147","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/bjc.2012.307","volume":"107","author":"U Wagner","year":"2012","unstructured":"Wagner, U. et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br. J. Cancer 107, 588\u2013591 (2012).","journal-title":"Br. J. Cancer"},{"key":"686_CR148","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian, C. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 30, 2039\u20132045 (2012).","journal-title":"J. Clin. Oncol."},{"key":"686_CR149","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine, E. et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. 32, 1302\u20131308 (2014).","journal-title":"J. Clin. Oncol."},{"key":"686_CR150","first-page":"850","volume":"57","author":"SW Johnson","year":"1997","unstructured":"Johnson, S. W., Laub, P. B., Beesley, J. S., Ozols, R. F. & Hamilton, T. C. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res. 57, 850\u2013856 (1997).","journal-title":"Cancer Res."},{"key":"686_CR151","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","volume":"385","author":"P Harter","year":"2021","unstructured":"Harter, P. et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N. Engl. J. Med. 385, 2123\u20132131 (2021).","journal-title":"N. Engl. J. Med."},{"key":"686_CR152","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/s41591-024-02981-0","volume":"30","author":"R Jiang","year":"2024","unstructured":"Jiang, R. et al. Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial. Nat. Med. 30, 2181\u20132188 (2024).","journal-title":"Nat. Med."},{"key":"686_CR153","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman, R. L. et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N. Engl. J. Med. 381, 1929\u20131939 (2019).","journal-title":"N. Engl. J. Med."},{"key":"686_CR154","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","volume":"13","author":"P Harter","year":"2006","unstructured":"Harter, P. et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann. Surg. Oncol. 13, 1702\u20131710 (2006). This trial demonstrated when surgery is an advantage in recurrent ovarian cancer.","journal-title":"Ann. Surg. Oncol."},{"key":"686_CR155","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","volume":"19","author":"WJ Tian","year":"2012","unstructured":"Tian, W. J. et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann. Surg. Oncol. 19, 597\u2013604 (2012).","journal-title":"Ann. Surg. Oncol."},{"key":"686_CR156","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","volume":"21","author":"J Pfisterer","year":"2020","unstructured":"Pfisterer, J. et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 21, 699\u2013709 (2020).","journal-title":"Lancet Oncol."},{"key":"686_CR157","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","volume":"361","author":"MK Parmar","year":"2003","unstructured":"Parmar, M. K. et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial. Lancet 361, 2099\u20132106 (2003).","journal-title":"Lancet"},{"key":"686_CR158","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"RL Coleman","year":"2017","unstructured":"Coleman, R. L. et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 18, 779\u2013791 (2017).","journal-title":"Lancet Oncol."},{"key":"686_CR159","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.annonc.2023.09.3110","volume":"34","author":"E Pujade-Lauraine","year":"2023","unstructured":"Pujade-Lauraine, E. et al. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT-ov38): a phase IIIb trial. Ann. Oncol. 34, 1152\u20131164 (2023).","journal-title":"Ann. Oncol."},{"key":"686_CR160","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda, A. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 620\u2013631 (2021).","journal-title":"Lancet Oncol."},{"key":"686_CR161","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/ijgc-2023-004995","volume":"34","author":"D Lorusso","year":"2024","unstructured":"Lorusso, D. et al. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial. Int. J. Gynecol. Cancer 34, 550\u2013558 (2024).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"686_CR162","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.annonc.2021.02.015","volume":"32","author":"T Baert","year":"2021","unstructured":"Baert, T. et al. The systemic treatment of recurrent ovarian cancer revisited. Ann. Oncol. 32, 710\u2013725 (2021).","journal-title":"Ann. Oncol."},{"key":"686_CR163","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","volume":"33","author":"AM Poveda","year":"2015","unstructured":"Poveda, A. M. et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J. Clin. Oncol. 33, 3836\u20133838 (2015).","journal-title":"J. Clin. Oncol."},{"key":"686_CR164","doi-asserted-by":"publisher","first-page":"e1435","DOI":"10.1093\/oncolo\/oyae177","volume":"29","author":"GK Dy","year":"2024","unstructured":"Dy, G. K., Farooq, A. V. & Kang, J. J. Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies. Oncologist 29, e1435\u2013e1451 (2024).","journal-title":"Oncologist"},{"key":"686_CR165","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1158\/1078-0432.CCR-23-0621","volume":"29","author":"RN Grisham","year":"2023","unstructured":"Grisham, R. N. et al. Molecular results and potential biomarkers identified from the phase 3 MILO\/ENGOT-ov11 study of binimetinib versus physician choice of chemotherapy in recurrent low-grade serous ovarian cancer. Clin. Cancer Res. 29, 4068\u20134075 (2023).","journal-title":"Clin. Cancer Res."},{"key":"686_CR166","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1200\/JCO.20.01164","volume":"38","author":"BJ Monk","year":"2020","unstructured":"Monk, B. J. et al. MILO\/ENGOT-ov11: binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. J. Clin. Oncol. 38, 3753\u20133762 (2020).","journal-title":"J. Clin. Oncol."},{"key":"686_CR167","unstructured":"US Food and Drug Administration. FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian cancer. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low (2025)."},{"key":"686_CR168","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT06072781 (2026)."},{"key":"686_CR169","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ygyno.2019.03.256","volume":"153","author":"M Gore","year":"2019","unstructured":"Gore, M. et al. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC\/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol. Oncol. 153, 541\u2013548 (2019).","journal-title":"Gynecol. Oncol."},{"key":"686_CR170","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/PROM.S297301","volume":"14","author":"R Campbell","year":"2023","unstructured":"Campbell, R. et al. Patient-reported outcomes in ovarian cancer: facilitating and enhancing the reporting of symptoms, adverse events, and subjective benefit of treatment in clinical trials and clinical practice. Patient Relat. Outcome Meas. 14, 111\u2013126 (2023).","journal-title":"Patient Relat. Outcome Meas."},{"key":"686_CR171","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ygyno.2021.02.018","volume":"161","author":"JE Kurtz","year":"2021","unstructured":"Kurtz, J. E. et al. Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: a position paper from the GCIG symptom benefit committee. Gynecol. Oncol. 161, 502\u2013507 (2021).","journal-title":"Gynecol. Oncol."},{"key":"686_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106860","volume":"120","author":"A Gnanasakthy","year":"2022","unstructured":"Gnanasakthy, A., Russo, J., Gnanasakthy, K., Harris, N. & Castro, C. A review of patient-reported outcome assessments in registration trials of FDA-approved new oncology drugs (2014-2018). Contemp. Clin. Trials 120, 106860 (2022).","journal-title":"Contemp. Clin. Trials"},{"key":"686_CR173","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-019-0538-9","volume":"12","author":"AS Kargo","year":"2019","unstructured":"Kargo, A. S., Coulter, A., Jensen, P. T. & Steffensen, K. D. Proactive use of PROMs in ovarian cancer survivors: a systematic review. J. Ovarian Res. 12, 63 (2019).","journal-title":"J. Ovarian Res."},{"key":"686_CR174","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211015958","volume":"12","author":"OL Aiyegbusi","year":"2021","unstructured":"Aiyegbusi, O. L., Nair, D., Peipert, J. D., Schick-Makaroff, K. & Mucsi, I. A narrative review of current evidence supporting the implementation of electronic patient-reported outcome measures in the management of chronic diseases. Ther. Adv. Chronic Dis. 12, 20406223211015958 (2021).","journal-title":"Ther. Adv. Chronic Dis."},{"key":"686_CR175","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jama.2018.18085","volume":"321","author":"F Denis","year":"2019","unstructured":"Denis, F. et al. Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer. JAMA 321, 306\u2013307 (2019).","journal-title":"JAMA"},{"key":"686_CR176","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/S2589-7500(22)00249-7","volume":"5","author":"FJ Pearce","year":"2023","unstructured":"Pearce, F. J. et al. The role of patient-reported outcome measures in trials of artificial intelligence health technologies: a systematic evaluation of ClinicalTrials.gov records (1997\u20132022). Lancet Digit. Health 5, e160\u2013e167 (2023).","journal-title":"Lancet Digit. Health"},{"key":"686_CR177","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1080\/07399330701876521","volume":"29","author":"J Power","year":"2008","unstructured":"Power, J., Brown, L. & Ritvo, P. A qualitative study examining psychosocial distress, coping, and social support across the stages and phases of epithelial ovarian cancer. Health Care Women Int. 29, 366\u2013383 (2008).","journal-title":"Health Care Women Int."},{"key":"686_CR178","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1017\/S1478951508000497","volume":"6","author":"D Schulman-Green","year":"2008","unstructured":"Schulman-Green, D., Ercolano, E., Dowd, M., Schwartz, P. & McCorkle, R. Quality of life among women after surgery for ovarian cancer. Palliat. Support. Care 6, 239\u2013247 (2008).","journal-title":"Palliat. Support. Care"},{"key":"686_CR179","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/GRF.0b013e3182480523","volume":"55","author":"B Goff","year":"2012","unstructured":"Goff, B. Symptoms associated with ovarian cancer. Clin. Obstet. Gynecol. 55, 36\u201342 (2012).","journal-title":"Clin. Obstet. Gynecol."},{"key":"686_CR180","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174318","volume":"13","author":"BP Rickard","year":"2021","unstructured":"Rickard, B. P. et al. Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. Cancers 13, 4318 (2021).","journal-title":"Cancers"},{"key":"686_CR181","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1634\/theoncologist.7-suppl_5-11","volume":"7","author":"CJ Dunton","year":"2002","unstructured":"Dunton, C. J. Management of treatment-related toxicity in advanced ovarian cancer. Oncologist 7, 11\u201319 (2002).","journal-title":"Oncologist"},{"key":"686_CR182","first-page":"7147","volume":"30","author":"V Pergialiotis","year":"2022","unstructured":"Pergialiotis, V. et al. Quality of life of ovarian cancer patients treated with combined platinum taxane chemotherapy: a systematic review of the literature. Support. Care Cancer 30, 7147\u20137157 (2022).","journal-title":"Support. Care Cancer"},{"key":"686_CR183","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ygyno.2020.07.029","volume":"159","author":"VL Beesley","year":"2020","unstructured":"Beesley, V. L. et al. When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer. Gynecol. Oncol. 159, 179\u2013186 (2020).","journal-title":"Gynecol. Oncol."},{"key":"686_CR184","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJMoa1000678","volume":"363","author":"JS Temel","year":"2010","unstructured":"Temel, J. S. et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N. Engl. J. Med. 363, 733\u2013742 (2010).","journal-title":"N. Engl. J. Med."},{"key":"686_CR185","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.annonc.2024.10.828","volume":"36","author":"P Harter","year":"2025","unstructured":"Harter, P. et al. Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1\/ENGOT-ov25 trial. Ann. Oncol. 36, 185\u2013196 (2025).","journal-title":"Ann. Oncol."},{"key":"686_CR186","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M. & de Vries, E. G. E. The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov. 14, 2089\u20132108 (2024).","journal-title":"Cancer Discov."},{"key":"686_CR187","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","volume":"9","author":"DL Richardson","year":"2023","unstructured":"Richardson, D. L., Eskander, R. N. & O\u2019Malley, D. M. Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review. JAMA Oncol. 9, 851\u2013859 (2023).","journal-title":"JAMA Oncol."},{"key":"686_CR188","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","volume":"14","author":"N Katsumata","year":"2013","unstructured":"Katsumata, N. et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 14, 1020\u20131026 (2013).","journal-title":"Lancet Oncol."},{"key":"686_CR189","first-page":"A424","volume":"33","author":"A Clamp","year":"2023","unstructured":"Clamp, A. et al. ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy\u2009+\u2009bevacizumab to three-weekly chemotherapy\u2009+\u2009bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment: primary progression-free survival analysis [abstract #159]. Int. J. Gynecol. Cancer 33, A424 (2023).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"686_CR190","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa1505067","volume":"374","author":"JK Chan","year":"2016","unstructured":"Chan, J. K., Brady, M. F. & Monk, B. J. Weekly vs. every-3-week paclitaxel for ovarian cancer. N. Engl. J. Med. 374, 2603\u20132604 (2016).","journal-title":"N. Engl. J. Med."},{"key":"686_CR191","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/jnci\/djh323","volume":"96","author":"PA Vasey","year":"2004","unstructured":"Vasey, P. A. et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl Cancer Inst. 96, 1682\u20131691 (2004).","journal-title":"J. Natl Cancer Inst."},{"key":"686_CR192","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","volume":"15","author":"S Pignata","year":"2014","unstructured":"Pignata, S. et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 15, 396\u2013405 (2014).","journal-title":"Lancet Oncol."},{"key":"686_CR193","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong, D. K. et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34\u201343 (2006).","journal-title":"N. Engl. J. Med."},{"key":"686_CR194","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495\u20132505 (2018).","journal-title":"N. Engl. J. Med."},{"key":"686_CR195","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","volume":"9","author":"N Li","year":"2023","unstructured":"Li, N. et al. Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial. JAMA Oncol. 9, 1230\u20131237 (2023).","journal-title":"JAMA Oncol."},{"key":"686_CR196","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine, E. et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28, 3323\u20133329 (2010).","journal-title":"J. Clin. Oncol."},{"key":"686_CR197","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","volume":"139","author":"C Aghajanian","year":"2015","unstructured":"Aghajanian, C. et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol. Oncol. 139, 10\u201316 (2015).","journal-title":"Gynecol. Oncol."},{"key":"686_CR198","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382\u20131392 (2012).","journal-title":"N. Engl. J. Med."},{"key":"686_CR199","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274\u20131284 (2017).","journal-title":"Lancet Oncol."},{"key":"686_CR200","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman, R. L. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 1949\u20131961 (2017).","journal-title":"Lancet"},{"key":"686_CR201","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza, M. R. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375, 2154\u20132164 (2016).","journal-title":"N. Engl. J. Med."},{"key":"686_CR202","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch, D. G. et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 25, 2811\u20132818 (2007).","journal-title":"J. Clin. Oncol."},{"key":"686_CR203","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore, K. N. et al. Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N. Engl. J. Med. 389, 2162\u20132174 (2023).","journal-title":"N. Engl. J. Med."},{"key":"686_CR204","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMra2108956","volume":"387","author":"RC Sisodia","year":"2022","unstructured":"Sisodia, R. C. & del Carmen, M. G. Lesions of the ovary and fallopian tube. N. Engl. J. Med. 387, 727\u2013736 (2022).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00686-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00686-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00686-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T08:02:12Z","timestamp":1772697732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00686-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":204,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["686"],"URL":"https:\/\/doi.org\/10.1038\/s41572-026-00686-x","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"3 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.L.S. reports grant and research support from AstraZeneca, Eisai Inc, Sierra Oncology, Boehringer Ingelheim and Ideaya; membership of advisory boards for AstraZeneca, Eisai Inc, Sierra Oncology, Roche, Takeda, MSD and GSK; and travel support from AstraZeneca, Illumina and Takeda. D.S.T. reports receipt of research grants to his institution from AstraZeneca, Bayer, Karyopharm Therapeutics and Roche; receipt of institutional funding as coordinating principal investigator from AstraZeneca, MSD, Eisai, Roche and Bergen Bio; receipt of institutional funding as local principal investigator from Roche, BioNTech, PMV Pharma, GSK, Sutro Pharma, Bayer, Byondis BV, Zymeworks and Zeria Pharmaceutical; receipt of research funding and salary support from the NMRC Clinician Scientist Award Senior Investigator Grant (CSASI21jun-0003); receipt of research funding from the Pangestu Family Foundation Gynaecological Cancer Research Fund, the Cancer Science Institute (Singapore) and the National University of Singapore; receipt of personal fees as an invited speaker from AstraZeneca, Eisai, GSK, Merck Serono, MSD, Roche, Daiichi Sankyo and Takeda; and receipt of personal fees for advisory board membership from AstraZeneca, Bayer, BioNTech, Boehringer Ingelheim, Eisai, Genmab, GSK, Daiichi Sankyo, MSD, Merck Serono, PMV Pharma and Roche. D.S.T. also reports ownership of stocks or shares of Asian Microbiome Library; previous non-remunerated roles as Chair of the Asia Pacific Gynecologic Oncology Trials Group, the Society President of the Gynecologic Cancer Group Singapore, and the Cervical Cancer Research Network of the GCIG; membership of the board of directors of the GCIG; and a current non-remunerated role as the Protocol Review Committee Chair for the Asia Pacific Gynecologic Oncology Trials Group. D.S.T. also reports product samples from AstraZeneca, Eisai and MSD (non-financial interest) for research trials. F.J. reports grant and research support from Ipsen, AZ and GSK; membership of advisory boards and\/or for lectures for AstraZeneca, Eisai Inc, MSD, GSK, Bayer, Astellas, Ipsen, Novartis, Daichii, Genmab and Amgen; and travel support from AstraZeneca, Esai, MSD, Novartis and Ipsen. S.B. reports consulting fees from Abbvie, AstraZeneca, Beigene, Biontech, Eisai, Epitopea, Gilead, GlaxoSmithKline, Grey Wolf Therapeutics, Immunogen, Incyte, ITM Oncologics, Lilly, Merck Sharpe Dohme, Mersana, Myriad, Oncxerna, Pharmaand, Seagen, TORL BioTherapeutics, Verastem and Zymeworks; honoraria from Abbvie, AstraZeneca, GlaxoSmithKline, Immunogen, Merck Sharpe Dohme, Mersana, Takeda, Verastem and Zymeworks; support for attending meetings from Astrazeneca, Lilly, Verastem and Zymeworks; and institutional funding from AstraZeneca and GlaxoSmithKline. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}